SCHEMBL1867972

SCHEMBL1867972

Cc1ccc(S(=O)(=O)NC(CN(C)C(=O)O)CC2(F)CCCCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
CA2 P00918 3/20 0.38
CA7 P43166 2/20 0.38
POLB P06746 1/20 0.38
CA1 P00915 2/20 0.38
CA9 Q16790 2/20 0.38
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
CA4 P22748 1/20 0.38
MMP1 P03956 1/20 0.38
MMP3 P08254 1/20 0.38
MMP7 P09237 1/20 0.38
MMP13 P45452 1/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1862912 0.86 MMP13 (0.37) TSHRHTTHSD17B10SLC1A3SLC1A2
SCHEMBL12631978 0.77 CA2 (0.41) TSHRHTTHSD17B10CA2CA7
SCHEMBL1863476 0.75 MMP13 (0.38) TSHRHTTHSD17B10SLC1A3SLC1A2
SCHEMBL1863963 0.73 HSD17B10 (0.35) TSHRHTTHSD17B10CA2POLB
SCHEMBL1863742 0.71 TSHR (0.42) TSHRHTTHSD17B10SLC1A3SLC1A2
SCHEMBL1864898 0.69 CA2 (0.43) TSHRHTTHSD17B10SLC1A3SLC1A2
SCHEMBL1867581 0.68 TSHR (0.43) TSHRHTTHSD17B10SLC1A3SLC1A2
SCHEMBL4869319 0.68 SLC1A3 (0.48) TSHRSLC1A3SLC1A2SLC1A1CA2
SCHEMBL4869315 0.68 SLC1A3 (0.48) TSHRSLC1A3SLC1A2SLC1A1CA2
SCHEMBL27829347 0.66 CA9 (0.43) TSHRHTTHSD17B10SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed
US-7754737-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-07-13 US disclosed
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors VITAE PHARMACEUTICAL, INC (US) 2009-01-15 US disclosed
EP-1807078-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed
WO-2006042150-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE TSHR 4650/4885HTT 2564/4885HSD17B10 1417/4885
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors DNPEP, PEPD, ACE TSHR 4650/4885HTT 2564/4885HSD17B10 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.